Clinical trial · Interventional
Peripheral Stem Cell Transplantation Followed By Infusion of White Blood Cells in Treating Patients With AIDS-Related Lymphoma
Delayed Donor Leukocyte Infusions in Patients Receiving Allogeneic PBSC Following Conditioning With Non-myeloablative Regimen for AIDS-Related Lymphoma (NHL and HD)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Withdrawn prior to initiation.
Summary
Brief summary (as posted)
RATIONALE: Donor peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy. Sometimes the transplanted cells are rejected by the body's normal tissues. Treatment with donor white blood cells may prevent this from happening. PURPOSE: Phase II trial to study the effectiveness of donor peripheral stem cell transplantation followed by infusions of donor white blood cells in treating patients who have AIDS-related lymphoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (6)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| anti-thymocyte globulin | Biological | — | UNRESOLVED |
| cyclophosphamide | Drug | Cyclophosphamide | ALIAS |
| cyclosporine | Drug | — | UNRESOLVED |
| peripheral blood stem cell transplantation | Procedure | — | UNRESOLVED |
| radiation therapy | Radiation | — | UNRESOLVED |
| therapeutic allogeneic lymphocytes | Biological | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 65 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Diagnosis of Hodgkin's disease or non-Hodgkin's lymphoma * Failed to achieve a complete remission with initial therapy OR * Relapsed after initial therapy * HIV-1 seropositive by Western Blot * Measurable or evaluable (e.g., pleural fluid involvement) disease * No leptomeningeal or parenchymal CNS involvement or active CNS leukemia * HLA-A, B, or DR antigen matched or 1 antigen mismatched related donor available * CD4 cell count greater than 100/mm3 (initial 12 patients) OR greater than 50/mm3 (subsequent patients)\* * HIV RNA less than 110,000 copies/mL\* NOTE: \*Unless not receiving optimal anti-retroviral therapy as defined by current clinical standards PATIENT CHARACTERISTICS: Age: * Physiologic 65 and under Performance status: * Karnofsky 70-100% Life expectancy: * Estimated disease-free survival less than 1 year Hematopoietic: * See Disease Characteristics Hepatic: * Bilirubin no greater than 2 mg/dL * Alkaline phosphatase no greater than 3 times upper limit of normal (ULN)\* * SGOT or SGPT no greater than 3 times ULN\* * Hepatitis B surface antigen negative NOTE: \*Unless receiving indinavir Renal: * Creatinine no greater than 1.5 mg/dL * Creatinine clearance at least 50 mL/min Cardiovascular: * No symptomatic congestive heart failure * No angina pectoris * No uncontrolled hypertension * LVEF at least 45% by radionuclide ventriculography Pulmonary: * No severe chronic obstructive lung disease * No symptomatic restrictive lung disease * DLCO greater than 50% predicted Other: * No active uncontrolled infection * No history of cytomegalovirus retinitis or pneumonitis, even if treated * No other disease that would limit life expectancy * No symptomatic leukoencephalopathy * No neuropsychiatric abnormalities that would preclude transplantation * Human T-cell lymphotrophic virus (HTLV-1) antibody negative * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for 3 months after study PRIOR CONCURRENT THERAPY: Biologic therapy: * Not specified Chemotherapy: * At least 1 week since prior chemotherapy Endocrine therapy: * Not specified Radiotherapy: * Not specified Surgery: * Not specified Other: * No concurrent chronic suppressive therapy
References
Publications (0)
Data not yet available